Sickle Cell Disease Treatment Market - By Treatment Modality [Blood Transfusion, Pharmacotherapy (Hydroxyurea, Oxybryta, Endari), Bone Marrow Transplant], By Disease (Sickle Cell Anemia, Hemoglobin Sickle C), By End-user & Forecast, 2023-2032

Sickle Cell Disease Treatment Market Size

Sickle Cell Disease Treatment Market size surpassed USD 2.38 billion in 2022 and is anticipated to exhibit lucrative CAGR of around 12.6% between 2023 and 2032. The growth is attributed to factors such as the growing prevalence of sickle cell diseases, increasing R&D activities regarding sickle cell disease treatment, and increasing healthcare expenditure and government initiatives.
 

Sickle cell disease is the most common inherited red blood cell disorder. It affects the oxygen-carrying protein haemoglobin, which is present in the blood. People with sickle cell disease inherit two faulty haemoglobin genes, known as haemoglobin S, from their parents. Usually, the red blood cells are round and flexible for easy passage through blood vessels. In the case of sickle cell disease, the red blood cells change their shape to resemble a crescent moon or sickle. These sickle cells become sticky and rigid and cause slow blood flow or may block the blood flow.
 

The management of sickle cell disease aims to avoid pain episodes, relieve the symptoms associated with the disease, and prevent complications. The treatment includes blood transfusions, medications, and bone marrow transplants.
 

COVID-19 Impact

During COVID-19, the global sickle cell disease treatment industry was obstructed due to the lockdown and travel restrictions imposed by the government all over the globe. Due to this, the number of people opting for sickle cell disease treatment and the number of hospitalizations decreased, hampering the sickle cell disease treatment market. For instance, in 2020, according to the Community Survey Report published by the National Organization of Rare Disorders (NORD) in the U.S., 74% of the 772 participants in the survey who suffered from a rare disease had cancelled their medical appointments due to travel restrictions and in order to avoid in-person contact. Later, as COVID instances decreased, the market experienced considerable growth as there was an increase in the number of patients opting for the treatments and new product launches.
 

Sickle Cell Disease Treatment Market Trends

The prevalence of sickle cell disease is increasing worldwide and significantly impacting the global market growth. According to the data presented by the WHO, in 2022, more than 66% of the 120 million people affected by sickle cell disease were from Africa. In Africa, 1,000 children are born with the disease every day. In Africa, in 2019, approximately 38403 deaths were recorded due to sickle cell disease. The high prevalence of this disease increases the demand for treatment options like blood infusions, pharmacotherapy, and bone marrow transplants. A high prevalence of sickle cell disease is reported in Africa, the Middle East, and India. The prevalence of sickle cell disease is increasing in other geographies along with migration.
 

Due to the increasing prevalence of sickle cell disease, pharmaceutical and biotechnology companies have increased their investment in R&D in order to develop new treatment options to treat various forms of sickle cell disease, such as sickle cell anemia, hemoglobin sickle C disease, and others. The increasing initiatives by government and private organizations for the treatment of sickle cell disease will drive the market in the coming years. For instance, in 2022, according to the data published by WHO, African health ministers have launched a campaign to increase awareness, bolster prevention, and provide care to reduce the toll of sickle cell disease, which is one of the most common diseases in this region.
 

Thus, pharmaceutical companies have increased research activities for the development of new sickle cell disease treatment products. The improved healthcare infrastructure, increasing healthcare expenditures, and R&D funding will propel the growth of this market.
 

Sickle Cell Disease Treatment Market Analysis

Based on treatment modality, the global sickle cell disease treatment market is subdivided into blood transfusion, pharmacotherapy, and bone marrow transplant. Pharmacotherapy is further subdivided on the basis of drug type and route of administration. On the basis of drug type, pharmacotherapy is classified into Hydroxyurea, Oxybryta, Adakveo, Endari, and other pharmacotherapies.
 

The blood transfusion segment dominated the market in 2022 with a revenue share of 65.1%. For sickle cell disease, blood transfusion has been considered the most effective treatment option to treat severe symptoms like strokes. Due to the rising number of episodes of stroke in sickle cell anemia patients, the demand for blood transfusion treatment has increased. Moreover, during the forecast period, the pharmacotherapy segment is anticipated to grow at a significant CAGR. Factors such as the introduction of new branded pharmacotherapy drugs, a strong pipeline, and increasing R&D activities fuel the market demand.
 

On the basis of drug type, the market for pharmacotherapy is subdivided into Hydroxyurea, Oxybryta, Adakveo, Endari, and other pharmacotherapies. Hydroxyurea segment dominated the market in 2022 and is expected to display significant growth. Hydroxyurea is an ideal drug for sickle cell disease patients by reducing the pain crisis and need for blood transfusion, due to which the demand and utilization of hydroxyurea are rising.
 

On the basis of route of administration, the market for pharmacotherapy is subdivided into oral and parenteral. The oral segment held the highest market share in 2022 owing to high adoption, non-invasiveness, patient compliance, and convenience. Many of the pharmacotherapy drugs are administered orally; for instance, hydroxyurea or Endari are available in tablet form.
 

Based on disease type, the global sickle cell disease treatment market is classified into sickle cell anemia, hemoglobin sickle C disease (HbSC), and other disease types. The sickle cell anemia segment accounted for the largest share in 2022 due to the high prevalence of sickle cell anemia. It is the most common and severe form of sickle cell disease, and the increasing complications associated with sickle cell anemia such as hemolysis or vaso-occlusive crises, are factors contributing to the growth of this segment.
 

Based on end-user, the global sickle cell disease treatment market is subdivided into hospitals, specialty clinics, and other end-users. Among the end-user segments, the hospital segment held the highest revenue share of the market in 2022. The increasing prevalence of sickle cell disease, development of new therapies for treating sickle cell disease, increasing government initiatives in launching the new drugs and increased number of admissions for sickle cell disease in hospitals accelerated the growth of this segment.
 

In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of sickle cell diseases, increasing investments for R&D for developing new drugs for treating sickle cell disease, presence of key players, and well-developed healthcare infrastructure. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the increasing prevalence of sickle cell disease and increased government initiatives and fundings.
 

In North America segment, U.S. accounted for the highest market share in 2022 due to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and increasing awareness and demand for sickle cell disease treatment.
 

Sickle Cell Disease Treatment Market Share

The key players in sickle cell disease treatment market are :

• Pfizer Inc
• Novartis AG
• Emmaus Medical Inc
• Medunik USA Inc.
• Bristol-Myers Squibb Company
• Bluebird Bio, Inc
• Agios Pharmaceuticals
• CRISPR Therapeutics
• Vifor Pharma
• Editas Medicine Inc

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
 

Sickle Cell Disease Treatment Industry News:

• In June 2020, Emmaus Medical, Inc. received approval from Israeli Ministry of Health for commercial distribution of Endari in Israel.
   
• In December 2022, Bluebird Bio Inc. announced that the US FDA had lifted a partial clinical hold on studies for its gene therapy to treat sickle cell disease.
   

The sickle cell disease treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Treatment Modality

• Blood transfusion
• Pharmacotherapy
  • By drug type
    • Hydroxyurea
    • Oxybryta
    • Adakveo
    • Endari
    • Other pharmacotherapies
  • By route of administration
    • Oral
    • Parenteral
• Bone marrow transplant

By Disease Type

• Sickle cell anemia
• Hemoglobin sickle C disease (HbSC)
• Other disease types

By End-user

• Hospitals
• Specialty clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA